Active ingredientEribulinCat. No. P-E084-001CAS 253128-41-5Family · Pharmaceutical analytical standards
Eribulin
An anticancer drug that blocks microtubules, a simplified and fully synthetic analogue of halichondrin B, isolated in 1986 in Japan from the marine sponge Halichondria okadai; approved in 2010 for metastatic breast cancer and in 2016 for liposarcoma. This family brings together the active ingredient and other impurities.
Did you know?A tonne of sponges yields just 300 mg of halichondrin B: the decisive step was the total synthesis of the molecule, completed in 1992 at Harvard by Yoshito Kishi's group.
Go to the active ingredient →Active ingredientEribulinCat. No. P-E084-001CAS 253128-41-5
Active ingredientEribulin MesylateCat. No. P-E084-002CAS 441045-17-6
ImpurityEribulin DiolCat. No. P-E084-003CAS 253128-15-3
ImpurityEribulin Impurity 1Cat. No. P-E084-004CAS 1534341-95-1
ImpurityEribulin Impurity 2Cat. No. P-E084-007CAS 2408645-13-4
ImpurityEribulin Impurity 3Cat. No. P-E084-008
ImpurityEribulin Impurity 4Cat. No. P-E084-009
ImpurityEribulin Impurity 5Cat. No. P-E084-010
ImpurityEribulin Impurity 6Cat. No. P-E084-011
ImpurityEribulin Impurity 7Cat. No. P-E084-012
ImpurityEribulin Impurity 8Cat. No. P-E084-014
ImpurityEribulin Impurity 9Cat. No. P-E084-019CAS 1422676-39-8
ImpurityEribulin Impurity 10Cat. No. P-E084-022
ImpurityEribulin Impurity 11Cat. No. P-E084-023
ImpurityEribulin Impurity 12Cat. No. P-E084-025CAS 253128-17-5
ImpurityEribulin Impurity 13Cat. No. P-E084-026CAS 1190395-92-6
ImpurityEribulin Impurity 14Cat. No. P-E084-029CAS 1534341-96-2
ImpurityEribulin Impurity 15Cat. No. P-E084-030CAS 157322-83-3
ImpurityEribulin Impurity 16Cat. No. P-E084-031CAS 253128-10-8
ImpurityEribulin Impurity 17Cat. No. P-E084-033CAS 157322-47-9
ImpurityEribulin Impurity 18Cat. No. P-E084-034CAS 871348-24-2
ImpurityEribulin Impurity 19Cat. No. P-E084-035CAS 1808153-90-3
ImpurityMethyl 3-(trimethylsilyl)-4-pentenoateCat. No. P-E084-036CAS 185411-12-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.